PIK-124

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 406322

CAS#: 711025-68-2

Description: PIK-124 is a potent PI3K inhibitor.


Price and Availability

Size
Price

10mg
Not available
100mg
Not available
1g
Ask price
10g
Ask price
Size
Price

25mg
Not available
200mg
Not available
2g
Ask price
20g
Ask price
Size
Price

50mg
Not available
500mg
Not available
5g
Ask price

PIK-124 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 406322
Name: PIK-124
CAS#: 711025-68-2
Chemical Formula: C19H12ClFN2O3S2
Exact Mass: 433.99619
Molecular Weight: 434.89
Elemental Analysis: C, 52.47; H, 2.78; Cl, 8.15; F, 4.37; N, 6.44; O, 11.04; S, 14.75


Synonym: PIK124; PIK 124; PIK-124.

IUPAC/Chemical Name: (E)-4-(3-chloro-4-fluorobenzyl)-6-((4-oxo-2-thioxothiazolidin-5-ylidene)methyl)-2H-benzo[b][1,4]oxazin-3(4H)-one

SMILES Code: O=C1N(CC2=CC=C(F)C(Cl)=C2)C3=CC(/C=C(SC(N4)=S)\C4=O)=CC=C3OC1


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs

Storage Condition:
0 – 4 oC for short term (weeks to 1 month) or -20 oC for long terms (months to years).

Solubility:
Soluble in DMSO, not soluble in water.

Shelf Life:
>2 years if stored properly.

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

  
 
 
 


References

1. Torbett, Neil E.; Luna-moran, Antonio; Knight, Zachary A.; Houk, Andrew; Moasser, Mark; Weiss, William; Shokat, Kevan M.; Stokoe, David. A chemical screen in diverse breast cancer cell lines reveals genetic enhancers and suppressors of sensitivity to PI3K isoform-selective inhibition. Biochemical Journal (2008), 415(1), 97-110

2. Kim, Tae-Wan; Dipaolo, Gilbert; Kang, Min Suk; Berman, Diego; McIntire, Laura Beth Johnson. Phosphoinositide modulation for the treatment of neurodegenerative diseases. PCT Int. Appl. (2008), WO 2008064244 A2 20080529

3. Knight, Zachary A.; Gonzalez, Beatriz; Feldman, Morri E.; Zunder, Eli R.; Goldenberg, David D.; Williams, Olusegun; Loewith, Robbie; Stokoe, David; Balla, Andras; Toth, Balazs; et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell (Cambridge, MA, United States) (2006), 125(4), 733-747.

4. Fan, Qi-Wen; Knight, Zachary A.; Goldenberg, David D.; Yu, Wei; Mostov, Keith E.; Stokoe, David; Shokat, Kevan M.; Weiss, William A. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell (2006), 9(5), 341-349.

5. Barvian, Nicole Chantel; Kolz, Christine Nylund; Para, Kimberly Suzanne; Patt, William Chester; Visnick, Melean. Preparation of benzoxazin-3-ones and derivatives as inhibitors of PI3K kinase for treating inflammations, cardiovascular diseases and cancers. PCT Int. Appl. (2004), WO 2004052373 A1 20040624.